España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
SEAGEN INC COM
SGEN
NASDAQ
Watchlist
Get Report
Perks
Buy
Compare Brokers
15 minutes delayed
Get Report
Watch
SEAGEN INC COM (SGEN) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for SEAGEN INC COM (NASDAQ:SGEN) Stock
SEAGEN INC COM Stock (NASDAQ: SGEN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, February 22, 2024
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Upwallstreet
Tuesday, January 02, 2024
How To Earn $500 A Month From Pfizer Stock
Avi Kapoor
Friday, December 29, 2023
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
Vandana Singh
Wednesday, December 20, 2023
Pharma Continues Its Ongoing Battle Against Cancer
Upwallstreet
Saturday, December 16, 2023
FDA Approves Expanded Indication For KEYTRUDA Plus Padcev For The First-Line Treatment Of Adult Patients With Locally Advanced Or Metastatic Urothelial Cancer
Happy Mohamed
Thursday, December 14, 2023
Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast
Nabaparna Bhattacharya
Pfizer Says It Completed Acquisition of Seage...
Benzinga Newsdesk
Wednesday, December 13, 2023
Looking Into Seagen's Recent Short Interest
Benzinga Insights
Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades'
Avi Kapoor
Why Is US Pharma Giant Pfizer Stock Trading Lower Today?
Vandana Singh
Tuesday, December 12, 2023
Seagen shares are trading higher after Pfizer...
Benzinga Newsdesk
Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition
Vandana Singh
Bristol Myers Squibb's Mega $8.4B Oncology Bet - Secures Exclusive License With SystImmune
Vandana Singh
Monday, December 11, 2023
What the Options Market Tells Us About Seagen
Benzinga Insights
Seagen's ADCETRIS® Plus Novel Immunotherapy C...
Benzinga Newsdesk
Friday, December 08, 2023
A Closer Look at Seagen's Options Market Dynamics
Benzinga Insights
Thursday, December 07, 2023
$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today
Benzinga Insights
Wednesday, December 06, 2023
TUKYSA In Combination With Antibody-Drug Conj...
Benzinga Newsdesk
Thursday, November 30, 2023
Seagen Says FDA Grants Priority Review For Su...
Benzinga Newsdesk
Monday, November 20, 2023
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,600 Today
Benzinga Insights
Friday, November 10, 2023
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Monday, November 06, 2023
This Is The 'Only Solar Stock' Jim Cramer Is Recommending 'Because It's A Pure Play'
Lisa Levin
Friday, November 03, 2023
Here's How Much You Would Have Made Owning Seagen Stock In The Last 15 Years
Benzinga Insights
Seagen Highlights First Solid Tumor Data For ...
Benzinga Newsdesk
Thursday, November 02, 2023
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Seagen Inc. Announces New Data For ADCETRIS W...
Benzinga Newsdesk
Wednesday, November 01, 2023
Looking At Seagen's Recent Unusual Options Activity
Benzinga Insights
Seagen's Proposed Pfizer Transaction On-Track...
Benzinga Newsdesk
Seagen Q3 EPS $(1.15) Misses $(0.79) Estimate...
Benzinga Newsdesk
Earnings Scheduled For November 1, 2023
Benzinga Insights
Tuesday, October 31, 2023
Earnings Outlook For Seagen
Benzinga Insights
Wednesday, October 25, 2023
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
Monday, October 23, 2023
(SGEN) - Analyzing Seagen's Short Interest
Benzinga Insights
Sunday, October 22, 2023
Seagen And Astellas Announced Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival In Patients Treated with PADCEV And KEYTRUDA In First-Line Advanced Bladder Cancer
Charles Gross
Genmab And Seagen Announced TIVDAK Significantly Prolonged Overall Survival In Patients with Recurrent Or Metastatic Cervical Cancer Compared With Chemotherapy In Global Phase 3 innovaTV 301 Trial
Charles Gross
Thursday, October 19, 2023
Pfizer Secures Unconditional EU Antitrust App...
Benzinga Newsdesk
Wednesday, October 18, 2023
Takeda Announces European Commission Approves ADCETRIS For The Treatment Of Adult Patients With Previously Untreated CD30+ Stage III Hodgkin Lymphoma In Combination With AVD
Happy Mohamed
Truist Securities Reiterates Hold on Seagen, ...
Benzinga Newsdesk
Tuesday, October 17, 2023
Here's How Much $1000 Invested In Seagen 5 Years Ago Would Be Worth Today
Benzinga Insights
Monday, October 16, 2023
Seagen To Highlight Overall Survival Data For...
Benzinga Newsdesk
Monday, October 09, 2023
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Friday, October 06, 2023
How Is The Market Feeling About Seagen?
Benzinga Insights
Thursday, October 05, 2023
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
Vandana Singh
Friday, September 29, 2023
If You Invested $100 In This Stock 20 Years Ago, You Would Have $3,400 Today
Benzinga Insights
Wednesday, September 27, 2023
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
Piero Cingari
Seagen Unusual Options Activity
Benzinga Insights
Monday, September 25, 2023
Truist Securities Reiterates Hold on Seagen, ...
Benzinga Newsdesk
Friday, September 22, 2023
Why Is Seagen Stock Trading Higher Today?
Vandana Singh
Seagen shares are trading higher after the co...
Benzinga Newsdesk
Seagen And Astellas Pharma Announced PADCEV And KEYTRUDA Significantly Improve Overall Survival And Progression-Free Survival In Patients With Previously Untreated Advanced Bladder Cancer In Pivotal Phase 3 EV-302 Trial
Charles Gross
Show More